Bone Density and Cardiovascular Risk in Men: The Overlooked Bidirectional Link

Men do not think of themselves as being at risk for osteoporosis. The condition carries, in popular perception, a strongly female association: the stooped posture, the hip fracture, the post-menopausal woman whose physician finally orders a bone density scan. This cultural framing is both inaccurate and medically costly. Men account for approximately one-third of all hip fractures globally, and male mortality following hip fracture is approximately twice the rate seen in women. But the stakes of this conversation for men extend beyond fracture risk. The same underlying biology that erodes bone in men also accelerates cardiovascular disease, and the epidemiological evidence connecting these two systems is stronger than most men, and many physicians, appreciate.

This article is about that connection: what drives it, what the evidence actually shows, why DEXA scanning is systematically underutilized in men, and what the intersection of bone health and cardiovascular risk means for the kind of integrated monitoring that men who are serious about their long-term health should be discussing with their physicians.

Shared Biological Drivers: Why the Connection Is Not Coincidental

The relationship between bone density and cardiovascular health in men is not mediated by a single mechanism. It reflects several converging biological pathways that damage both systems simultaneously, which means that low bone density in a man is not just a skeleton problem. It is a metabolic signal.

The most prominent shared driver is testosterone deficiency. Testosterone plays an important role in bone maintenance in men through its direct action on osteoblasts (the cells that build bone) and through its conversion to estradiol via aromatase, since estradiol is the primary sex hormone responsible for inhibiting osteoclast-mediated bone resorption in both sexes. When testosterone falls, bone remodeling shifts toward net resorption, and bone mineral density declines. The same testosterone decline also affects the cardiovascular system: testosterone deficiency in men is associated with increased visceral adiposity, insulin resistance, dyslipidemia with elevated triglycerides and reduced HDL, impaired endothelial function, and increased inflammatory markers. 4 / Promising Low testosterone does not merely damage bone and the cardiovascular system independently. It creates a metabolic environment in which both deteriorate together.

Vitamin D deficiency is a second major shared driver. Vitamin D receptors are present on osteoblasts, cardiomyocytes, vascular smooth muscle cells, and endothelial cells, reflecting the hormone’s broad systemic role beyond calcium metabolism. Vitamin D deficiency impairs intestinal calcium absorption and osteoblast function, accelerating bone loss. In the cardiovascular system, vitamin D deficiency is associated with increased renin-angiotensin-aldosterone system activation, which raises blood pressure; with impaired endothelial function and reduced nitric oxide bioavailability; and with elevated parathyroid hormone, which has its own adverse vascular effects. 4 / Promising Epidemiological studies consistently show associations between low vitamin D levels and increased risk of cardiovascular events, though the causal direction and whether supplementation alters outcomes remains an active area of investigation.

Chronic inflammation is the third shared pathway. Inflammatory cytokines, particularly interleukin-1, interleukin-6, and tumor necrosis factor-alpha, activate osteoclasts and accelerate bone resorption while simultaneously driving endothelial dysfunction, promoting atherosclerotic plaque formation, and destabilizing existing plaques. Conditions that generate sustained low-grade systemic inflammation, including visceral obesity, chronic stress, sleep apnea, and periodontal disease, damage bone and blood vessels through overlapping inflammatory mechanisms. A man with chronically elevated C-reactive protein is, biologically, at risk in both compartments simultaneously.

Sedentary behavior is the fourth shared driver, and it is the most modifiable. Mechanical loading through weight-bearing exercise is one of the most potent stimuli for osteoblast activity and bone formation. Men who are sedentary deprive their skeletons of this osteogenic stimulus while simultaneously losing the cardiovascular and metabolic benefits of regular physical activity: improved endothelial function, reduced insulin resistance, lower blood pressure, and favorable effects on lipid profiles. The same lifestyle that builds cardiovascular risk builds bone loss risk.

Why Men’s Bone Loss Goes Undetected

The systematic underutilization of DEXA scanning in men is one of the more consequential gaps in preventive medicine for the male cardiovascular patient. Current U.S. Preventive Services Task Force guidelines recommend DEXA screening for osteoporosis in women aged 65 and older, and for younger women with elevated fracture risk. For men, there is no equivalent USPSTF recommendation, and most male bone density loss is not detected until a fragility fracture occurs.

This gap exists for several reasons. Men’s bone density declines more gradually than the accelerated perimenopausal decline in women, meaning the condition progresses more slowly and is therefore less visible in clinical cross-sections. Men’s bone loss does not occur in the context of a discrete hormonal transition the way women’s does, so there is no equivalent clinical trigger that prompts screening. And the cultural framing of osteoporosis as a female condition influences which patients clinicians think to screen.

The clinical cost of this gap is substantial. By the time a man sustains a vertebral compression fracture or a hip fracture, bone density has often been in the osteoporotic range for years. And the cardiovascular implications of that fracture are significant, as the epidemiological evidence shows.

Certain male patients warrant bone density evaluation based on their clinical profile, and this is a conversation that belongs in the physician’s office. Men who have been on androgen deprivation therapy for prostate cancer, who have used long-term glucocorticoids, who have hypogonadism from any cause, who have had bariatric surgery, or who have a history of fragility fracture are among those for whom your physician may consider DEXA evaluation earlier than population screening guidelines would suggest. Your cardiologist or primary care physician can discuss whether your specific risk profile warrants bone density assessment.

The Epidemiological Evidence: Vertebral Fractures and Cardiovascular Mortality in Men

The epidemiological data connecting bone events to cardiovascular mortality in men is one of the most underappreciated findings in this space, and it warrants careful attention.

Multiple large prospective studies have found that vertebral fractures in men are independent predictors of increased cardiovascular mortality, even after adjusting for traditional cardiovascular risk factors. The mechanism of this association is not fully resolved. The leading explanations are not mutually exclusive. First, vertebral fractures may directly increase cardiovascular mortality through reduced respiratory capacity: compression fractures in the thoracic spine alter thoracic cage geometry, reducing tidal volume and functional residual capacity, which impairs oxygenation and increases demand on a cardiovascular system that may already be under stress. Second, vertebral fractures may serve as late clinical signals of shared underlying pathology that has been progressing in both the skeleton and the vasculature for years: the man who sustains a vertebral fracture at 70 may have been accumulating bone and vascular damage since his late 40s. The fracture is not the cause of his cardiovascular risk. It is the signal that the underlying drivers have been operating without detection.

A study by Pasco and colleagues using data from the Geelong Osteoporosis Study found that men with vertebral fractures had significantly higher cardiovascular mortality over ten years of follow-up compared to age-matched men without fractures, independent of bone density alone. 3 / Early Similar associations have been reported in Scandinavian registry data and in the European Vertebral Osteoporosis Study cohort.

Hip fractures in men carry an even bleaker short-term prognosis. Approximately 25 to 30% of men who sustain a hip fracture die within the following year, compared to roughly 15 to 20% of women, likely reflecting the older average age of male hip fracture patients and greater pre-existing comorbidity burden. A significant proportion of those deaths are cardiovascular, occurring in men whose perioperative cardiovascular reserve is insufficient to withstand the hemodynamic stress of surgical repair and postoperative recovery.

The Calcium Paradox: Bone, Arteries, and Vascular Calcification

One of the most conceptually important findings in the bone-cardiovascular connection is what is sometimes called the calcium paradox: the observation that men who are losing calcium from bone simultaneously tend to have calcium accumulating in their arterial walls. The same ion that should be in bone is being deposited in a place where it accelerates cardiovascular disease.

Vascular calcification, the deposition of calcium phosphate mineral in the intima and media of arterial walls, is a well-established independent predictor of cardiovascular events. Coronary artery calcium score, measured by CT, is one of the stronger reclassification tools in cardiovascular risk assessment for intermediate-risk patients. Medial calcification in peripheral arteries stiffens vessels, increases pulse wave velocity, elevates systolic blood pressure, widens pulse pressure, and increases cardiac afterload. These are direct hemodynamic mechanisms of cardiovascular harm. 5 / Solid

The calcium paradox arises because vascular calcification and bone loss share regulatory machinery. Osteocalcin, matrix Gla protein, and other vitamin K-dependent proteins normally inhibit calcium deposition in vascular walls while facilitating its incorporation into bone mineral. When these regulatory proteins are undercarboxylated, as occurs with vitamin K2 deficiency, their ability to inhibit vascular calcification is impaired while bone mineralization is simultaneously less efficient. 3 / Early This is the mechanistic basis for the current scientific interest in vitamin K2 as a modifier of the bone-vascular calcium balance, though the clinical evidence base for supplementation in humans remains early-stage and should not be translated into self-directed supplement decisions without physician involvement.

Vitamin D adds another layer to this picture. Vitamin D is required for calcium absorption, and its deficiency reduces calcium uptake from the gut, promoting secondary hyperparathyroidism. Elevated parathyroid hormone mobilizes calcium from bone to maintain serum calcium levels, contributing to bone loss while simultaneously creating conditions that may favor calcium deposition in soft tissues including arterial walls. Whether vitamin D supplementation in men who are deficient improves the bone-vascular calcium balance in a clinically meaningful way remains under investigation. Your physician may consider vitamin D levels as part of a comprehensive cardiovascular and bone risk assessment.

Androgen Deprivation Therapy: The Simultaneous Accelerant

Androgen deprivation therapy (ADT) for prostate cancer represents the most clinically concentrated example of the bone-cardiovascular connection in men, because ADT removes testosterone rapidly and completely, simultaneously accelerating bone loss and increasing cardiovascular risk across multiple pathways.

Men on ADT lose bone mineral density at rates of approximately 2 to 5% per year, compared to age-matched men not on ADT, who lose bone at approximately 0.5 to 1% per year. This accelerated bone loss begins within the first year of therapy and produces clinically significant osteopenia and osteoporosis within two to three years in a substantial proportion of men. Vertebral fractures and hip fractures in men on long-term ADT are documented at rates substantially higher than in age-matched men not receiving ADT. 5 / Solid

Simultaneously, ADT increases cardiovascular risk through multiple pathways. ADT increases insulin resistance, body fat (particularly visceral fat), LDL cholesterol, and triglycerides within months of initiation. It reduces lean muscle mass and exercise capacity. Studies have found associations between ADT use and increased risks of myocardial infarction, stroke, and cardiovascular death, though the magnitude of risk varies by patient age, baseline cardiovascular risk, and the specific ADT regimen used. The FDA added a warning to ADT labels in 2010 noting the increased risks of diabetes and cardiovascular disease. 5 / Solid

The clinical implication for men with prostate cancer who are considering or receiving ADT is that bone health and cardiovascular health should be monitored simultaneously and proactively, rather than being addressed separately in different specialty silos. Your oncologist, cardiologist, and primary care physician may benefit from coordinating on the monitoring and risk-reduction strategy for men on ADT, particularly for long-duration therapy. This is a conversation your cardiologist can help structure if it is not already occurring.

Testosterone, Bone, and the Clinical Hypogonadism Picture

Outside the ADT context, hypogonadism from other causes produces the same pattern of simultaneous bone and cardiovascular deterioration, though more gradually. Men with primary hypogonadism (from testicular failure), secondary hypogonadism (from pituitary or hypothalamic dysfunction), or functional hypogonadism (from obesity, chronic illness, or opioid use) all share the same downstream consequence: insufficient testosterone to maintain bone remodeling balance and metabolic health.

The relationship between testosterone levels and cardiovascular risk in men has been studied extensively and the results are more nuanced than either the hormone replacement industry or its critics have fully represented. Very low testosterone (below roughly 200 to 250 ng/dL in the context of symptoms) is consistently associated with worse cardiovascular risk markers. The association at the low-normal range (300 to 450 ng/dL) is less clear and likely highly dependent on individual metabolic context. Whether testosterone replacement therapy improves cardiovascular outcomes for hypogonadal men is an important unanswered question, with ongoing trials including the TRAVERSE trial providing some recent data. Your physician may discuss testosterone levels and their relevance to your specific cardiovascular and bone risk profile.

Practical Implications: What Integrated Monitoring Looks Like

The clinical implication of the bone-cardiovascular connection is not that every man needs a DEXA scan tomorrow. It is that bone density, which is not currently part of routine cardiovascular risk assessment in men, may provide additional signal that is clinically useful when integrated with other cardiovascular risk information.

A man in his mid-fifties who presents for cardiovascular risk assessment with hypertension, borderline LDL, mildly elevated fasting glucose, and low-normal testosterone is, from a bone perspective, carrying the same upstream risk factors that will erode his skeleton over the next decade. The DEXA result for that man is not irrelevant to his cardiovascular care. It is a window into how aggressively the shared underlying drivers have been operating.

Your cardiologist may discuss whether bone density evaluation makes sense for your particular risk profile. The conversation is most clearly indicated if you have known hypogonadism, have used long-term glucocorticoids, have a history of fragility fracture, are on or being considered for ADT, or have a combination of risk factors that suggest accelerated metabolic aging. Men with established cardiovascular disease and any of these additional risk factors represent a population where the bidirectional risk picture is most clinically concentrated.

Exercise is the intervention that most directly addresses both sides of this connection simultaneously. Weight-bearing and resistance exercise stimulates osteoblast activity and bone formation while producing established cardiovascular benefits through improvements in endothelial function, blood pressure, insulin sensitivity, and lipid profiles. For men whose bone-cardiovascular risk is driven in part by sedentary lifestyle, structured resistance and aerobic exercise may be the most powerful single intervention available, and it is one that your physician or a certified exercise physiologist can help you structure appropriately for your cardiovascular baseline.

The Missing Conversation in Men’s Health

The bone-cardiovascular connection is a conversation that happens infrequently in men’s health, for reasons that are partly cultural, partly guideline-driven, and partly structural: bone health specialists and cardiovascular specialists rarely share the same clinical visit. But the biology that connects these systems does not respect clinical silos.

For men who are engaged enough in their cardiovascular health to be reading evidence-based content about risk reduction, the bone picture deserves a place in that conversation. Not because osteoporosis is the primary cardiovascular threat, but because the shared underlying drivers that erode bone and damage blood vessels are the same modifiable factors that comprehensive cardiovascular risk management should be addressing in any case.

Low testosterone, vitamin D deficiency, chronic inflammation, sedentary lifestyle, and conditions like ADT that sharply accelerate both processes simultaneously: these are the threads that connect the skeleton and the cardiovascular system in men. Pulling on those threads through integrated medical monitoring and lifestyle change is more powerful than addressing either system in isolation.

Frequently Asked Questions

Q: Why do men rarely get bone density scans compared to women? A: Several factors contribute to this disparity. Current USPSTF screening recommendations apply to women aged 65 and older but do not include equivalent guidance for men. Men’s bone loss is more gradual than the accelerated post-menopausal decline in women, making it less visible in clinical practice. The cultural association of osteoporosis with women also influences clinical awareness. Men with specific risk factors, including hypogonadism, long-term glucocorticoid use, androgen deprivation therapy, or prior fragility fracture, may warrant earlier evaluation, which is a discussion to have with your physician.

Q: What is the connection between a vertebral fracture and dying from a heart attack? A: The association is epidemiological and likely reflects shared underlying pathology rather than a direct causal mechanism. A man who sustains a vertebral fracture may have the same chronic inflammation, testosterone deficiency, or metabolic dysfunction driving both the bone loss and the vascular disease. The fracture is a late signal of upstream damage. Additionally, thoracic vertebral fractures can reduce lung capacity and increase cardiovascular strain through mechanical effects on the thoracic cage. Whether addressing bone health specifically reduces cardiovascular mortality has not been tested in outcomes trials.

Q: What is the calcium paradox in the context of bone and heart health? A: The calcium paradox refers to the observation that bone calcium loss and arterial calcium deposition can occur simultaneously in the same person. Calcium that should remain in bone mineral is instead deposited in arterial walls, a process called vascular calcification that stiffens arteries and increases cardiovascular risk. Vitamin K-dependent proteins normally prevent vascular calcium deposition while promoting bone calcification. When these proteins are underactive, as may occur with vitamin K2 deficiency, both processes may go wrong at once. The clinical implications for supplementation are not yet firmly established, and this is an area to discuss with your physician rather than self-manage.

Q: Does androgen deprivation therapy for prostate cancer really increase cardiovascular risk? A: Yes, and the evidence is substantial enough that the FDA added cardiovascular warnings to ADT labels in 2010. ADT increases insulin resistance, visceral fat, LDL, and triglycerides within months of initiation, and epidemiological studies have found associations with increased rates of myocardial infarction, stroke, and cardiovascular death. Simultaneously, ADT accelerates bone loss at a rate of 2 to 5% per year. Men who need ADT for prostate cancer management should discuss the cardiovascular and bone implications with their oncologist and cardiologist together, so that monitoring and risk reduction strategies are coordinated rather than siloed.

Q: Should men with low bone density be concerned about their heart? A: Not alarmed, but informed. Low bone density in a man is a signal that the shared upstream drivers of bone and cardiovascular deterioration may have been operating for some time. It is clinically useful context for a cardiovascular physician to have, particularly in combination with other risk factors. The appropriate response is to discuss the finding with your physician in the context of your full cardiovascular risk profile, not to assume a direct causal link between bone density and imminent cardiac events.